4.5 Article

Structure-Activity Relationship Study of Covalent Pan-phosphatidylinositol 5-Phosphate 4-Kinase Inhibitors

Journal

ACS MEDICINAL CHEMISTRY LETTERS
Volume 11, Issue 3, Pages 346-352

Publisher

AMER CHEMICAL SOC
DOI: 10.1021/acsmedchemlett.9b00402

Keywords

PI5P4K; lipid kinase inhibitors; structure-activity relationship; covalent inhibitors; phosphoinositide; drug discovery

Funding

  1. National Institutes of Health [R01 CA197329, R01 NS089815, R03 MH096575, R01 CA222218, R03 CA250020, R35 CA197588, R01 GM041890, U54 CA210184]
  2. Breast Cancer Research Foundation
  3. NIH intramural research program (NCATS)

Ask authors/readers for more resources

Phosphatidylinositol 5-phosphate 4-kinases (PI5P4Ks) are important molecular players in a variety of diseases, such as cancer. Currently available PI5P4K inhibitors are reversible small molecules, which may lack selectivity and sufficient cellular on-target activity. In this study, we present a new class of covalent pan-PI5P4K inhibitors with potent biochemical and cellular activity. Our designs are based on THZ-P1-2, a covalent PI5P4K inhibitor previously developed in our lab. Here, we report further structure-guided optimization and structure-activity relationship (SAR) study of this scaffold, resulting in compound 30, which retained biochemical and cellular potency, while demonstrating a significantly improved selectivity profile. Furthermore, we confirm that the inhibitors show efficient binding affinity in the context of HEK 293T cells using isothermal CETSA methods. Taken together, compound 30 represents a highly selective pan-PI5P4K covalent lead molecule.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available